AstraZeneca: promising results in leukemia

(CercleFinance.com) - AstraZeneca announces that results from a Phase III trial showed that the combination of Calquence (acalabrutinib) and venetoclax, with or without obinutuzumab, significantly reduced the risk of chronic lymphocytic leukemia (CLL) progression or death compared to standard chemotherapy.


At a median follow-up of 41 months, the risk reduction reached 35% for Calquence plus venetoclax alone, and 58% with obinutuzumab.

The fixed, all-oral treatment demonstrated durable progression-free survival (PFS), surpassing the 47.6 months of chemotherapy.

The results will be presented at ASH 2024.


Copyright (c) 2024 CercleFinance.com. All rights reserved.